Chiu, H.-Y. et al. 2015. Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis. Acta Dermato-Venereologica. 95, 6 (Feb. 2015), 711–716. DOI:https://doi.org/10.2340/00015555-2069.